JP2017520569A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017520569A5 JP2017520569A5 JP2016575150A JP2016575150A JP2017520569A5 JP 2017520569 A5 JP2017520569 A5 JP 2017520569A5 JP 2016575150 A JP2016575150 A JP 2016575150A JP 2016575150 A JP2016575150 A JP 2016575150A JP 2017520569 A5 JP2017520569 A5 JP 2017520569A5
- Authority
- JP
- Japan
- Prior art keywords
- disease
- syndrome
- jnk inhibitor
- eye
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 26
- 239000012825 JNK inhibitor Substances 0.000 claims 21
- 229940118135 JNK inhibitor Drugs 0.000 claims 21
- 229940024606 amino acid Drugs 0.000 claims 17
- 235000001014 amino acid Nutrition 0.000 claims 17
- 150000001413 amino acids Chemical group 0.000 claims 17
- 208000003556 Dry Eye Syndromes Diseases 0.000 claims 16
- 201000010099 disease Diseases 0.000 claims 14
- 206010013774 Dry eye Diseases 0.000 claims 12
- 208000021386 Sjogren Syndrome Diseases 0.000 claims 12
- 208000035475 disorder Diseases 0.000 claims 9
- 208000017442 Retinal disease Diseases 0.000 claims 6
- 206010038923 Retinopathy Diseases 0.000 claims 6
- 208000024827 Alzheimer disease Diseases 0.000 claims 5
- 201000004624 Dermatitis Diseases 0.000 claims 5
- 208000011580 syndromic disease Diseases 0.000 claims 5
- 206010047115 Vasculitis Diseases 0.000 claims 4
- 210000002216 heart Anatomy 0.000 claims 4
- 210000003734 kidney Anatomy 0.000 claims 4
- 210000003491 skin Anatomy 0.000 claims 4
- 210000001519 tissue Anatomy 0.000 claims 4
- 108010078791 Carrier Proteins Proteins 0.000 claims 3
- 150000008574 D-amino acids Chemical class 0.000 claims 3
- 206010016654 Fibrosis Diseases 0.000 claims 3
- 206010034277 Pemphigoid Diseases 0.000 claims 3
- 206010064930 age-related macular degeneration Diseases 0.000 claims 3
- 125000000539 amino acid group Chemical group 0.000 claims 3
- 230000002401 inhibitory effect Effects 0.000 claims 3
- 208000002780 macular degeneration Diseases 0.000 claims 3
- 108090000765 processed proteins & peptides Proteins 0.000 claims 3
- 208000002574 reactive arthritis Diseases 0.000 claims 3
- 208000002874 Acne Vulgaris Diseases 0.000 claims 2
- 208000008190 Agammaglobulinemia Diseases 0.000 claims 2
- 206010003267 Arthritis reactive Diseases 0.000 claims 2
- 206010018364 Glomerulonephritis Diseases 0.000 claims 2
- 208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 claims 2
- 206010020983 Hypogammaglobulinaemia Diseases 0.000 claims 2
- 206010061218 Inflammation Diseases 0.000 claims 2
- 208000003456 Juvenile Arthritis Diseases 0.000 claims 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims 2
- 206010065159 Polychondritis Diseases 0.000 claims 2
- 201000004681 Psoriasis Diseases 0.000 claims 2
- 206010038933 Retinopathy of prematurity Diseases 0.000 claims 2
- 208000009415 Spinocerebellar Ataxias Diseases 0.000 claims 2
- 208000024780 Urticaria Diseases 0.000 claims 2
- 206010000496 acne Diseases 0.000 claims 2
- 208000002552 acute disseminated encephalomyelitis Diseases 0.000 claims 2
- 230000005784 autoimmunity Effects 0.000 claims 2
- 210000001185 bone marrow Anatomy 0.000 claims 2
- 208000016651 cerebral cortex disease Diseases 0.000 claims 2
- 208000010877 cognitive disease Diseases 0.000 claims 2
- 206010014599 encephalitis Diseases 0.000 claims 2
- 230000004761 fibrosis Effects 0.000 claims 2
- 208000027866 inflammatory disease Diseases 0.000 claims 2
- 230000002757 inflammatory effect Effects 0.000 claims 2
- 230000004054 inflammatory process Effects 0.000 claims 2
- 201000006334 interstitial nephritis Diseases 0.000 claims 2
- 201000011486 lichen planus Diseases 0.000 claims 2
- 210000004185 liver Anatomy 0.000 claims 2
- 210000004072 lung Anatomy 0.000 claims 2
- 208000027061 mild cognitive impairment Diseases 0.000 claims 2
- 201000008383 nephritis Diseases 0.000 claims 2
- 210000000056 organ Anatomy 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 230000000750 progressive effect Effects 0.000 claims 2
- 201000000306 sarcoidosis Diseases 0.000 claims 2
- 206010043778 thyroiditis Diseases 0.000 claims 2
- 230000000699 topical effect Effects 0.000 claims 2
- 206010056508 Acquired epidermolysis bullosa Diseases 0.000 claims 1
- 208000026872 Addison Disease Diseases 0.000 claims 1
- 208000032671 Allergic granulomatous angiitis Diseases 0.000 claims 1
- 208000022099 Alzheimer disease 2 Diseases 0.000 claims 1
- 206010001935 American trypanosomiasis Diseases 0.000 claims 1
- 208000003343 Antiphospholipid Syndrome Diseases 0.000 claims 1
- 208000036487 Arthropathies Diseases 0.000 claims 1
- 102000014461 Ataxins Human genes 0.000 claims 1
- 108010078286 Ataxins Proteins 0.000 claims 1
- 206010003645 Atopy Diseases 0.000 claims 1
- 206010071576 Autoimmune aplastic anaemia Diseases 0.000 claims 1
- 206010003827 Autoimmune hepatitis Diseases 0.000 claims 1
- 208000000659 Autoimmune lymphoproliferative syndrome Diseases 0.000 claims 1
- 206010069002 Autoimmune pancreatitis Diseases 0.000 claims 1
- 208000031212 Autoimmune polyendocrinopathy Diseases 0.000 claims 1
- 208000022106 Autoimmune polyendocrinopathy type 2 Diseases 0.000 claims 1
- 208000023328 Basedow disease Diseases 0.000 claims 1
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 claims 1
- 208000033222 Biliary cirrhosis primary Diseases 0.000 claims 1
- 208000009766 Blau syndrome Diseases 0.000 claims 1
- 201000002829 CREST Syndrome Diseases 0.000 claims 1
- 208000005024 Castleman disease Diseases 0.000 claims 1
- 206010008025 Cerebellar ataxia Diseases 0.000 claims 1
- 208000024699 Chagas disease Diseases 0.000 claims 1
- 206010008609 Cholangitis sclerosing Diseases 0.000 claims 1
- 206010008685 Chondritis Diseases 0.000 claims 1
- 206010008748 Chorea Diseases 0.000 claims 1
- 208000030939 Chronic inflammatory demyelinating polyneuropathy Diseases 0.000 claims 1
- 208000006344 Churg-Strauss Syndrome Diseases 0.000 claims 1
- 208000015943 Coeliac disease Diseases 0.000 claims 1
- 208000011038 Cold agglutinin disease Diseases 0.000 claims 1
- 206010009868 Cold type haemolytic anaemia Diseases 0.000 claims 1
- 206010010252 Concentric sclerosis Diseases 0.000 claims 1
- 208000014311 Cushing syndrome Diseases 0.000 claims 1
- 206010012289 Dementia Diseases 0.000 claims 1
- 208000016192 Demyelinating disease Diseases 0.000 claims 1
- 206010012438 Dermatitis atopic Diseases 0.000 claims 1
- 206010012442 Dermatitis contact Diseases 0.000 claims 1
- 208000007342 Diabetic Nephropathies Diseases 0.000 claims 1
- 206010012689 Diabetic retinopathy Diseases 0.000 claims 1
- 208000006926 Discoid Lupus Erythematosus Diseases 0.000 claims 1
- 208000021866 Dressler syndrome Diseases 0.000 claims 1
- 102000004190 Enzymes Human genes 0.000 claims 1
- 108090000790 Enzymes Proteins 0.000 claims 1
- 208000018428 Eosinophilic granulomatosis with polyangiitis Diseases 0.000 claims 1
- 206010015150 Erythema Diseases 0.000 claims 1
- 206010015226 Erythema nodosum Diseases 0.000 claims 1
- 208000004332 Evans syndrome Diseases 0.000 claims 1
- 201000011240 Frontotemporal dementia Diseases 0.000 claims 1
- 208000007882 Gastritis Diseases 0.000 claims 1
- 208000005577 Gastroenteritis Diseases 0.000 claims 1
- 208000007465 Giant cell arteritis Diseases 0.000 claims 1
- 206010018367 Glomerulonephritis chronic Diseases 0.000 claims 1
- 206010018372 Glomerulonephritis membranous Diseases 0.000 claims 1
- 208000024869 Goodpasture syndrome Diseases 0.000 claims 1
- 206010018691 Granuloma Diseases 0.000 claims 1
- 206010072579 Granulomatosis with polyangiitis Diseases 0.000 claims 1
- 208000015023 Graves' disease Diseases 0.000 claims 1
- 208000035895 Guillain-Barré syndrome Diseases 0.000 claims 1
- 208000030836 Hashimoto thyroiditis Diseases 0.000 claims 1
- 208000029470 Hughes-Stovin syndrome Diseases 0.000 claims 1
- 206010020751 Hypersensitivity Diseases 0.000 claims 1
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 claims 1
- 206010021245 Idiopathic thrombocytopenic purpura Diseases 0.000 claims 1
- 208000014919 IgG4-related retroperitoneal fibrosis Diseases 0.000 claims 1
- 208000012659 Joint disease Diseases 0.000 claims 1
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 claims 1
- 208000011200 Kawasaki disease Diseases 0.000 claims 1
- 150000008575 L-amino acids Chemical class 0.000 claims 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 claims 1
- 229930064664 L-arginine Natural products 0.000 claims 1
- 235000014852 L-arginine Nutrition 0.000 claims 1
- 235000019454 L-leucine Nutrition 0.000 claims 1
- 239000004395 L-leucine Substances 0.000 claims 1
- 208000009829 Lewy Body Disease Diseases 0.000 claims 1
- 201000002832 Lewy body dementia Diseases 0.000 claims 1
- 208000005995 Lichenoid Eruptions Diseases 0.000 claims 1
- 208000012309 Linear IgA disease Diseases 0.000 claims 1
- 208000000185 Localized scleroderma Diseases 0.000 claims 1
- 208000005777 Lupus Nephritis Diseases 0.000 claims 1
- 206010050551 Lupus-like syndrome Diseases 0.000 claims 1
- 208000009777 Majeed syndrome Diseases 0.000 claims 1
- 208000027530 Meniere disease Diseases 0.000 claims 1
- 201000009906 Meningitis Diseases 0.000 claims 1
- 241001465754 Metazoa Species 0.000 claims 1
- 206010049567 Miller Fisher syndrome Diseases 0.000 claims 1
- 208000026072 Motor neurone disease Diseases 0.000 claims 1
- 208000001089 Multiple system atrophy Diseases 0.000 claims 1
- 206010028372 Muscular weakness Diseases 0.000 claims 1
- 206010052904 Musculoskeletal stiffness Diseases 0.000 claims 1
- 208000000112 Myalgia Diseases 0.000 claims 1
- 208000003926 Myelitis Diseases 0.000 claims 1
- 201000002481 Myositis Diseases 0.000 claims 1
- 206010058105 Neutrophilic dermatosis Diseases 0.000 claims 1
- 208000005225 Opsoclonus-Myoclonus Syndrome Diseases 0.000 claims 1
- 208000003435 Optic Neuritis Diseases 0.000 claims 1
- 208000007117 Oral Ulcer Diseases 0.000 claims 1
- 206010031252 Osteomyelitis Diseases 0.000 claims 1
- 206010031264 Osteonecrosis Diseases 0.000 claims 1
- 206010053869 POEMS syndrome Diseases 0.000 claims 1
- 206010033645 Pancreatitis Diseases 0.000 claims 1
- 206010048705 Paraneoplastic cerebellar degeneration Diseases 0.000 claims 1
- 208000000733 Paroxysmal Hemoglobinuria Diseases 0.000 claims 1
- 208000008223 Pemphigoid Gestationis Diseases 0.000 claims 1
- 208000006389 Peri-Implantitis Diseases 0.000 claims 1
- 208000031845 Pernicious anaemia Diseases 0.000 claims 1
- 102100036050 Phosphatidylinositol N-acetylglucosaminyltransferase subunit A Human genes 0.000 claims 1
- 208000037062 Polyps Diseases 0.000 claims 1
- 208000012654 Primary biliary cholangitis Diseases 0.000 claims 1
- 208000024777 Prion disease Diseases 0.000 claims 1
- 208000037534 Progressive hemifacial atrophy Diseases 0.000 claims 1
- 208000020410 Psoriasis-related juvenile idiopathic arthritis Diseases 0.000 claims 1
- 201000004328 Pulpitis Diseases 0.000 claims 1
- 206010037464 Pulpitis dental Diseases 0.000 claims 1
- 206010037596 Pyelonephritis Diseases 0.000 claims 1
- 208000006311 Pyoderma Diseases 0.000 claims 1
- 206010071141 Rasmussen encephalitis Diseases 0.000 claims 1
- 208000004160 Rasmussen subacute encephalitis Diseases 0.000 claims 1
- 208000012322 Raynaud phenomenon Diseases 0.000 claims 1
- 208000033464 Reiter syndrome Diseases 0.000 claims 1
- 208000005793 Restless legs syndrome Diseases 0.000 claims 1
- 206010038926 Retinopathy hypertensive Diseases 0.000 claims 1
- 206010038979 Retroperitoneal fibrosis Diseases 0.000 claims 1
- 208000025747 Rheumatic disease Diseases 0.000 claims 1
- 201000010848 Schnitzler Syndrome Diseases 0.000 claims 1
- 208000034189 Sclerosis Diseases 0.000 claims 1
- 208000006045 Spondylarthropathies Diseases 0.000 claims 1
- 201000002661 Spondylitis Diseases 0.000 claims 1
- 208000002286 Susac Syndrome Diseases 0.000 claims 1
- 206010042742 Sympathetic ophthalmia Diseases 0.000 claims 1
- 201000009594 Systemic Scleroderma Diseases 0.000 claims 1
- 206010042953 Systemic sclerosis Diseases 0.000 claims 1
- 208000001106 Takayasu Arteritis Diseases 0.000 claims 1
- 208000034799 Tauopathies Diseases 0.000 claims 1
- 208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 claims 1
- 208000026062 Tissue disease Diseases 0.000 claims 1
- 206010052779 Transplant rejections Diseases 0.000 claims 1
- 241000223109 Trypanosoma cruzi Species 0.000 claims 1
- 206010048302 Tubulointerstitial nephritis Diseases 0.000 claims 1
- 208000026928 Turner syndrome Diseases 0.000 claims 1
- 206010047642 Vitiligo Diseases 0.000 claims 1
- 206010000269 abscess Diseases 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- 208000026935 allergic disease Diseases 0.000 claims 1
- 230000007815 allergy Effects 0.000 claims 1
- 208000004631 alopecia areata Diseases 0.000 claims 1
- 206010002022 amyloidosis Diseases 0.000 claims 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 1
- 208000037849 arterial hypertension Diseases 0.000 claims 1
- 206010003246 arthritis Diseases 0.000 claims 1
- 201000008937 atopic dermatitis Diseases 0.000 claims 1
- 208000010668 atopic eczema Diseases 0.000 claims 1
- 201000004984 autoimmune cardiomyopathy Diseases 0.000 claims 1
- 201000000448 autoimmune hemolytic anemia Diseases 0.000 claims 1
- 208000027625 autoimmune inner ear disease Diseases 0.000 claims 1
- 201000004339 autoimmune neuropathy Diseases 0.000 claims 1
- 201000005011 autoimmune peripheral neuropathy Diseases 0.000 claims 1
- 201000011385 autoimmune polyendocrine syndrome Diseases 0.000 claims 1
- 201000009780 autoimmune polyendocrine syndrome type 2 Diseases 0.000 claims 1
- 206010071572 autoimmune progesterone dermatitis Diseases 0.000 claims 1
- 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 claims 1
- 201000004562 autosomal dominant cerebellar ataxia Diseases 0.000 claims 1
- 210000004227 basal ganglia Anatomy 0.000 claims 1
- 210000000601 blood cell Anatomy 0.000 claims 1
- 210000004204 blood vessel Anatomy 0.000 claims 1
- 210000000988 bone and bone Anatomy 0.000 claims 1
- 210000004556 brain Anatomy 0.000 claims 1
- 208000000594 bullous pemphigoid Diseases 0.000 claims 1
- 210000004899 c-terminal region Anatomy 0.000 claims 1
- 208000003167 cholangitis Diseases 0.000 claims 1
- 208000012601 choreatic disease Diseases 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 201000005795 chronic inflammatory demyelinating polyneuritis Diseases 0.000 claims 1
- 208000025302 chronic primary adrenal insufficiency Diseases 0.000 claims 1
- 230000007882 cirrhosis Effects 0.000 claims 1
- 208000019425 cirrhosis of liver Diseases 0.000 claims 1
- 230000000295 complement effect Effects 0.000 claims 1
- 210000000795 conjunctiva Anatomy 0.000 claims 1
- 208000010247 contact dermatitis Diseases 0.000 claims 1
- 210000004087 cornea Anatomy 0.000 claims 1
- 201000003278 cryoglobulinemia Diseases 0.000 claims 1
- 208000004921 cutaneous lupus erythematosus Diseases 0.000 claims 1
- 201000003146 cystitis Diseases 0.000 claims 1
- 230000007812 deficiency Effects 0.000 claims 1
- 230000007850 degeneration Effects 0.000 claims 1
- 201000001981 dermatomyositis Diseases 0.000 claims 1
- 208000033679 diabetic kidney disease Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 201000004997 drug-induced lupus erythematosus Diseases 0.000 claims 1
- 208000025688 early-onset autosomal dominant Alzheimer disease Diseases 0.000 claims 1
- 208000037902 enteropathy Diseases 0.000 claims 1
- 230000002327 eosinophilic effect Effects 0.000 claims 1
- 201000001564 eosinophilic gastroenteritis Diseases 0.000 claims 1
- 201000009580 eosinophilic pneumonia Diseases 0.000 claims 1
- 210000002615 epidermis Anatomy 0.000 claims 1
- 201000011114 epidermolysis bullosa acquisita Diseases 0.000 claims 1
- 231100000321 erythema Toxicity 0.000 claims 1
- 230000003203 everyday effect Effects 0.000 claims 1
- 208000002980 facial hemiatrophy Diseases 0.000 claims 1
- 230000003176 fibrotic effect Effects 0.000 claims 1
- 201000005206 focal segmental glomerulosclerosis Diseases 0.000 claims 1
- 231100000854 focal segmental glomerulosclerosis Toxicity 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- 230000002496 gastric effect Effects 0.000 claims 1
- 208000007565 gingivitis Diseases 0.000 claims 1
- 210000003709 heart valve Anatomy 0.000 claims 1
- 230000002949 hemolytic effect Effects 0.000 claims 1
- 208000006454 hepatitis Diseases 0.000 claims 1
- 231100000283 hepatitis Toxicity 0.000 claims 1
- 208000008675 hereditary spastic paraplegia Diseases 0.000 claims 1
- 201000001948 hypertensive retinopathy Diseases 0.000 claims 1
- 201000008319 inclusion body myositis Diseases 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 230000002458 infectious effect Effects 0.000 claims 1
- 208000014674 injury Diseases 0.000 claims 1
- 208000036971 interstitial lung disease 2 Diseases 0.000 claims 1
- 208000028774 intestinal disease Diseases 0.000 claims 1
- 230000000968 intestinal effect Effects 0.000 claims 1
- 210000000936 intestine Anatomy 0.000 claims 1
- 238000007918 intramuscular administration Methods 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 210000001503 joint Anatomy 0.000 claims 1
- 201000002215 juvenile rheumatoid arthritis Diseases 0.000 claims 1
- 206010023332 keratitis Diseases 0.000 claims 1
- 208000017169 kidney disease Diseases 0.000 claims 1
- 229960003136 leucine Drugs 0.000 claims 1
- 210000001370 mediastinum Anatomy 0.000 claims 1
- 201000008350 membranous glomerulonephritis Diseases 0.000 claims 1
- 231100000855 membranous nephropathy Toxicity 0.000 claims 1
- 201000008265 mesangial proliferative glomerulonephritis Diseases 0.000 claims 1
- 206010063344 microscopic polyangiitis Diseases 0.000 claims 1
- 208000005264 motor neuron disease Diseases 0.000 claims 1
- 208000001725 mucocutaneous lymph node syndrome Diseases 0.000 claims 1
- 210000003205 muscle Anatomy 0.000 claims 1
- 230000036473 myasthenia Effects 0.000 claims 1
- 206010028417 myasthenia gravis Diseases 0.000 claims 1
- 201000003631 narcolepsy Diseases 0.000 claims 1
- 230000002232 neuromuscular Effects 0.000 claims 1
- 201000001119 neuropathy Diseases 0.000 claims 1
- 230000007823 neuropathy Effects 0.000 claims 1
- 230000011164 ossification Effects 0.000 claims 1
- 210000000496 pancreas Anatomy 0.000 claims 1
- 201000003045 paroxysmal nocturnal hemoglobinuria Diseases 0.000 claims 1
- 201000001245 periodontitis Diseases 0.000 claims 1
- 208000033808 peripheral neuropathy Diseases 0.000 claims 1
- 208000005987 polymyositis Diseases 0.000 claims 1
- 201000009395 primary hyperaldosteronism Diseases 0.000 claims 1
- 201000000742 primary sclerosing cholangitis Diseases 0.000 claims 1
- 201000002212 progressive supranuclear palsy Diseases 0.000 claims 1
- 201000008171 proliferative glomerulonephritis Diseases 0.000 claims 1
- 201000009732 pulmonary eosinophilia Diseases 0.000 claims 1
- 230000005855 radiation Effects 0.000 claims 1
- 201000008158 rapidly progressive glomerulonephritis Diseases 0.000 claims 1
- 230000000306 recurrent effect Effects 0.000 claims 1
- 208000009169 relapsing polychondritis Diseases 0.000 claims 1
- 210000000574 retroperitoneal space Anatomy 0.000 claims 1
- 230000000552 rheumatic effect Effects 0.000 claims 1
- 201000003068 rheumatic fever Diseases 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 231100000241 scar Toxicity 0.000 claims 1
- 201000000980 schizophrenia Diseases 0.000 claims 1
- 208000010157 sclerosing cholangitis Diseases 0.000 claims 1
- 210000002966 serum Anatomy 0.000 claims 1
- 210000002832 shoulder Anatomy 0.000 claims 1
- 208000017520 skin disease Diseases 0.000 claims 1
- 201000005671 spondyloarthropathy Diseases 0.000 claims 1
- 230000007863 steatosis Effects 0.000 claims 1
- 231100000240 steatosis hepatitis Toxicity 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
- 238000001356 surgical procedure Methods 0.000 claims 1
- 210000004243 sweat Anatomy 0.000 claims 1
- 230000009885 systemic effect Effects 0.000 claims 1
- 206010043207 temporal arteritis Diseases 0.000 claims 1
- 210000002435 tendon Anatomy 0.000 claims 1
- 206010043554 thrombocytopenia Diseases 0.000 claims 1
- 238000002054 transplantation Methods 0.000 claims 1
- 208000009174 transverse myelitis Diseases 0.000 claims 1
- 230000008733 trauma Effects 0.000 claims 1
- 238000009736 wetting Methods 0.000 claims 1
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/EP2013/001880 WO2014206426A1 (en) | 2013-06-26 | 2013-06-26 | New use for jnk inhibitor molecules for treatment of various diseases |
| EPPCT/EP2014/001737 | 2014-06-26 | ||
| PCT/EP2014/001737 WO2014206564A1 (en) | 2013-06-26 | 2014-06-26 | New use for jnk inhibitor molecules for treatment of various diseases |
| EPPCT/EP2014/002723 | 2014-10-08 | ||
| PCT/EP2014/002723 WO2015197097A1 (en) | 2014-06-26 | 2014-10-08 | New use for jnk inhibitor molecules for treatment of various diseases |
| PCT/EP2015/001293 WO2015197193A2 (en) | 2014-06-26 | 2015-06-26 | New use for jnk inhibitor molecules for treatment of various diseases |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017520569A JP2017520569A (ja) | 2017-07-27 |
| JP2017520569A5 true JP2017520569A5 (cg-RX-API-DMAC7.html) | 2018-07-26 |
| JP6843625B2 JP6843625B2 (ja) | 2021-03-17 |
Family
ID=48771388
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016522322A Pending JP2016523275A (ja) | 2013-06-26 | 2014-06-26 | 多様な疾患を処置するためのｊｎｋ阻害剤分子の新規な用途 |
| JP2016575150A Expired - Fee Related JP6843625B2 (ja) | 2013-06-26 | 2015-06-26 | 様々な疾患の処置のためのｊｎｋ阻害剤分子の新規使用 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016522322A Pending JP2016523275A (ja) | 2013-06-26 | 2014-06-26 | 多様な疾患を処置するためのｊｎｋ阻害剤分子の新規な用途 |
Country Status (4)
| Country | Link |
|---|---|
| US (3) | US20160115200A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3013853A1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP2016523275A (cg-RX-API-DMAC7.html) |
| WO (2) | WO2014206426A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007031098A1 (en) | 2005-09-12 | 2007-03-22 | Xigen S.A. | Cell-permeable peptide inhibitors of the jnk signal transduction pathway |
| WO2009143865A1 (en) | 2008-05-30 | 2009-12-03 | Xigen S.A. | Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases |
| WO2009143864A1 (en) | 2008-05-30 | 2009-12-03 | Xigen S.A. | Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of chronic or non-chronic inflammatory digestive diseases |
| WO2010072228A1 (en) | 2008-12-22 | 2010-07-01 | Xigen S.A. | Novel transporter constructs and transporter cargo conjugate molecules |
| WO2011160653A1 (en) | 2010-06-21 | 2011-12-29 | Xigen S.A. | Novel jnk inhibitor molecules |
| AU2010362444B2 (en) | 2010-10-14 | 2015-08-06 | Xigen Inflammation Ltd. | Use of cell-permeable peptide inhibitors of the JNK signal transduction pathway for the treatment of chronic or non-chronic inflammatory eye diseases |
| WO2013091670A1 (en) | 2011-12-21 | 2013-06-27 | Xigen S.A. | Novel jnk inhibitor molecules for treatment of various diseases |
| WO2015197097A1 (en) | 2014-06-26 | 2015-12-30 | Xigen Inflammation Ltd. | New use for jnk inhibitor molecules for treatment of various diseases |
| WO2016055160A2 (en) * | 2014-10-08 | 2016-04-14 | Xigen Inflammation Ltd. | New use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases |
| WO2014206427A1 (en) | 2013-06-26 | 2014-12-31 | Xigen Inflammation Ltd. | New use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases |
| AU2014301631A1 (en) | 2013-06-26 | 2015-08-27 | Xigen Inflammation Ltd. | New use of cell-permeable peptide inhibitors of the JNK signal transduction pathway for the treatment of various diseases |
| WO2014206426A1 (en) * | 2013-06-26 | 2014-12-31 | Xigen Inflammation Ltd. | New use for jnk inhibitor molecules for treatment of various diseases |
| ES2949982T3 (es) * | 2014-06-26 | 2023-10-04 | Xigen Inflammation Ltd | Inhibidores peptídicos permeables en células de la ruta de transducción de señales de JNK para el tratamiento de la cistitis |
| WO2015200768A2 (en) * | 2014-06-26 | 2015-12-30 | Auris Medical Ag | Pharmacologic treatments of menière's disease |
| JP2025069480A (ja) * | 2022-03-25 | 2025-05-01 | メスキュージェナシス株式会社 | ジンジパインに対して親和性及び／又は阻害能を有するペプチド及びその使用 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5674980A (en) | 1989-12-21 | 1997-10-07 | Biogen Inc | Fusion protein comprising tat-derived transport moiety |
| US5804604A (en) | 1989-12-21 | 1998-09-08 | Biogen, Inc. | Tat-derived transport polypeptides and fusion proteins |
| BR9610058A (pt) | 1995-07-28 | 1999-07-27 | Marie Curie Cancer Care | Uso de vp22 ou uma porção ativa fragmento ou homólogo do mesmo proteína de transporte ácido nucleíco vetor de expressão célula hospedeira de mamíferos ou microbiana e processos para transportar uma proteína ou peptídeo desejado para uma população de marcaç o de células e para transportar uma molécula desejada em uma população de células |
| US6043083A (en) | 1997-04-28 | 2000-03-28 | Davis; Roger J. | Inhibitors of the JNK signal transduction pathway and methods of use |
| EP1075271A4 (en) * | 1998-04-17 | 2002-09-25 | Univ Maryland | METHOD FOR TREATING INTERSTITIAL CYSTITIS USING A GROWTH FACTOR LIKE THE EPIDERMAL RECOMBINANT GROWTH FACTOR ATTACHING TO HEPARIN (HB-EGF) |
| US20030108539A1 (en) * | 2000-02-14 | 2003-06-12 | Christophe Bonny | Cell-permeable peptide inhibitors of the JNK signal transduction pathway |
| MXPA05005101A (es) * | 2002-11-15 | 2005-09-08 | Sangstat Medical Corp | Peptidos de citomodulacion para el tratamiento de cistitis intersticial. |
| WO2007031098A1 (en) | 2005-09-12 | 2007-03-22 | Xigen S.A. | Cell-permeable peptide inhibitors of the jnk signal transduction pathway |
| JP2009538882A (ja) * | 2006-06-02 | 2009-11-12 | メルク セローノ ソシエテ アノニム | 皮膚疾患の治療のためのｊｎｋ阻害物質 |
| WO2009143865A1 (en) * | 2008-05-30 | 2009-12-03 | Xigen S.A. | Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases |
| EA201171188A1 (ru) | 2009-03-30 | 2012-05-30 | Сантен Фармасьютикал Ко., Лтд. | Профилактическое или терапевтическое средство против болезни сетчатки и способ профилактики или лечения болезни сетчатки с использованием jnk (c-jun-аминоконцевая киназа)-ингибиторного пептида, а также применение указанного пептида |
| WO2010151638A1 (en) | 2009-06-25 | 2010-12-29 | Medical College Of Georgia Research Institute, Inc. | Jnk inhibitors for use in treating spinal muscular atrophy |
| GB2478599B (en) * | 2010-03-12 | 2014-07-16 | Dyson Technology Ltd | A vacuum cleaning arrangement |
| WO2011160653A1 (en) * | 2010-06-21 | 2011-12-29 | Xigen S.A. | Novel jnk inhibitor molecules |
| AU2010362444B2 (en) * | 2010-10-14 | 2015-08-06 | Xigen Inflammation Ltd. | Use of cell-permeable peptide inhibitors of the JNK signal transduction pathway for the treatment of chronic or non-chronic inflammatory eye diseases |
| MX2014006399A (es) * | 2011-11-30 | 2015-04-10 | Xigen Inflammation Ltd | Uso de inhibidores de peptidos con celulas permeables de la via para transduccion de señal de jnk para el tratamiento de la queratoconjuntivitis seca. |
| WO2013091670A1 (en) * | 2011-12-21 | 2013-06-27 | Xigen S.A. | Novel jnk inhibitor molecules for treatment of various diseases |
| AU2014301631A1 (en) * | 2013-06-26 | 2015-08-27 | Xigen Inflammation Ltd. | New use of cell-permeable peptide inhibitors of the JNK signal transduction pathway for the treatment of various diseases |
| WO2014206426A1 (en) * | 2013-06-26 | 2014-12-31 | Xigen Inflammation Ltd. | New use for jnk inhibitor molecules for treatment of various diseases |
-
2013
- 2013-06-26 WO PCT/EP2013/001880 patent/WO2014206426A1/en not_active Ceased
-
2014
- 2014-06-26 JP JP2016522322A patent/JP2016523275A/ja active Pending
- 2014-06-26 WO PCT/EP2014/001737 patent/WO2014206564A1/en not_active Ceased
- 2014-06-26 EP EP14736292.5A patent/EP3013853A1/en not_active Withdrawn
- 2014-06-26 US US14/890,859 patent/US20160115200A1/en not_active Abandoned
-
2015
- 2015-06-26 JP JP2016575150A patent/JP6843625B2/ja not_active Expired - Fee Related
- 2015-06-26 US US15/321,904 patent/US20170128516A1/en not_active Abandoned
-
2022
- 2022-04-12 US US17/719,068 patent/US20220280591A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017520569A5 (cg-RX-API-DMAC7.html) | ||
| JP2017520571A5 (cg-RX-API-DMAC7.html) | ||
| ES2610159T3 (es) | Aptámeros para ß-NGF y su uso en el tratamiento de enfermedades y trastornos mediados por ß-NGF | |
| MY153979A (en) | Substituted piperidino-dihydrothienopyrimidine | |
| BRPI0820112B8 (pt) | derivados de isoxazol-piridina, seu uso e processos de preparação e medicamento | |
| CN109922821A (zh) | 使用新型杂合actriib配体陷阱蛋白治疗肌肉萎缩和骨病的方法 | |
| BRPI0408369A (pt) | derivados de indol úteis para o tratamento de doenças | |
| NO20064726L (no) | Imidazolforbindelser for behandling av neurodegenerative forstyrrelser | |
| NO20085326L (no) | Pyrido[3,2-e]pyraziner, deres anvendelser som inhibitorer av fosfodiesterase 10, og fremgangsmater for fremstilling av dem | |
| EA201390712A1 (ru) | Производные пиридазина, композиции и способы лечения когнитивного нарушения | |
| AU2015348944A1 (en) | Substituted bridged urea analogs as sirtuin modulators | |
| EA202190323A1 (ru) | ИМИДАЗО[1,2-b]ПИРИДАЗИНЫ В КАЧЕСТВЕ ИНГИБИТОРОВ Trk | |
| ZA201003519B (en) | Piperidinyl and piperazinyl modulators of y-secretase | |
| Povarnina et al. | Neuropeptide cycloprolylglycine exhibits neuroprotective activity after systemic administration to rats with modeled incomplete global ischemia and in in vitro modeled glutamate neurotoxicity | |
| ATE512147T1 (de) | Makrozyklische aminiopyridyl-beta-sekretase- hemmer zur behandlung von morbus alzheimer | |
| NO20081845L (no) | Imidazolforbindelser for behandling av neurologiske lidelser | |
| EA202190322A1 (ru) | ИМИДАЗО[1,2-b]ПИРИДАЗИНОВЫЕ ПРОИЗВОДНЫЕ В КАЧЕСТВЕ ИНГИБИТОРОВ TRK | |
| KR20230022456A (ko) | Akt3 조절제 | |
| RU2012100241A (ru) | Лечение хориоидальной неоваскуляризации с помощью вакцин | |
| EA200401520A1 (ru) | Фармацевтические композиции для лечения заболеваний, связанных с нейротрофинами | |
| KR20240116620A (ko) | Akt3 조절제 | |
| PE20060498A1 (es) | Amidas del acido 5 y 6-aminoalquil indol-2-carboxilico 3-sustituidas y analogos relacionados como inhibidores de la caseina cinasa i(epsilon) | |
| JP7757312B2 (ja) | Ａｋｔ３モジュレーター | |
| HK40084847A (en) | Akt3 modulators | |
| JP2024541994A (ja) | Ａｋｔ３モジュレーター |